Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON 2 10 versus ETRAFON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON 2 10 versus ETRAFON A.
ETRAFON 2-10 vs ETRAFON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON 2-10 is a combination of the phenothiazine antipsychotic perphenazine and the tricyclic antidepressant amitriptyline. Perphenazine blocks dopamine D2 receptors, reducing dopaminergic neurotransmission in the mesolimbic pathway, while amitriptyline inhibits serotonin and norepinephrine reuptake, enhancing monoaminergic signaling.
ETRAFON-A is a combination of perphenazine (a typical antipsychotic) and amitriptyline (a tricyclic antidepressant). Perphenazine blocks dopamine D2 receptors, while amitriptyline inhibits serotonin and norepinephrine reuptake.
1-2 tablets (perphenazine 2 mg / amitriptyline 10 mg) orally 3-4 times daily; max 8 tablets/day.
Etrafon-A (perphenazine 4 mg/amitriptyline 10 mg) is not FDA-approved; typical dosing per manufacturer: 1 tablet 3-4 times daily, up to 4 tablets/day. Route: oral.
None Documented
None Documented
The terminal elimination half-life is approximately 9-10 hours for perphenazine and 18-24 hours for amitriptyline; amitriptyline's active metabolite nortriptyline has a half-life of 18-44 hours, necessitating once-daily dosing for maintenance.
Terminal elimination half-life: 18-36 hours (mean 24 h); context: in elderly or hepatic impairment may extend beyond 48 h, requiring dose adjustment.
Elimination is primarily renal (50-70% as metabolites, <5% unchanged) and biliary/fecal (30-50% as metabolites).
Renal: 50-60% as unchanged drug and metabolites (primarily glucuronide conjugates); Biliary/Fecal: 30-40%; up to 10% excreted via sweat/saliva.
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic/Antidepressant Combination